Skip to content
Casandra.AI | Sponsored Testing logo
  • Companion Diagnostics
  • List Your Program
  • About Casandra
  • Contact Sales
  • Sign In
  • Companion Diagnostics
  • List Your Program
  • About Casandra
  • Contact Sales
  • Sign In

Ovarian Cancer

Disease/Condition(s): epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer
What is Ovarian Cancer?

Doctors know that ovarian cancer begins when cells in or near the ovaries develop changes (mutations) in their DNA. A cell’s DNA contains the instructions that tell the cell what to do. The changes tell the cells to grow and multiply quickly, creating a mass (tumor) of cancer cells. The cancer cells continue living when healthy cells would die. They can invade nearby tissues and break off from an initial tumor to spread (metastasize) to other parts of the body.

Ovarian Cancer Sponsored Testing Program Overview:

Ovarian Cancer (FR-ASSIST™)

FOLR1 IHC

FOLR1 IHC testing offered at no charge
Order Test
Learn More
What is the role of testing for Ovarian Cancer?

Folate receptor alpha (FRα) is an actionable biomarker that is important to assess in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.  ELAHERE™ (mirvetuximab soravtansine-gynx) is the first and only treatment indicated for adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC), who have received one to three prior systemic treatment regimens.

The VENTANA RxDx FOLR1 IHC assay is an FDA-approved companion diagnostic assay that can detect the level of FRα expression. Patients with EOC whose tumors highly express FRα (≥75% tumor cells staining at 2+/3+ intensity) may be eligible for treatment with ELAHERE.

What is the Program?

AbbVie offers the ImmunoGen FR-ASSIST™ FOLR1 Immunohistochemistry (IHC) Sponsored Testing Program as a way to increase access to testing for patients with epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC). The program also assists healthcare providers with making informed treatment decisions for these patients. Under an arrangement with ImmunoGen, FOLR1 IHC testing is available at no cost for patients with EOC that meet certain eligibility requirements.

– While AbbVie provides financial support for this program, tests and services are performed by diagnostic labs.
Healthcare professionals must confirm that patients meet certain criteria to use the program.
– AbbVie receives de-identified aggregate data from this program, but at no time does the sponsor receive patient-identifiable information. The sponsor may use healthcare professional contact information for research and commercial purposes.
– Healthcare professionals or patients who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any sponsor product.
– No patients, healthcare professionals, or payers, including government payers, are billed for this program.

Program Eligibility

Patients must meet all of the following criteria to be eligible:

  • Patient has epithelial ovarian cancer, fallopian tube or primary peritoneal cancer
  • Patient lives and receives treatment in the United States or a US Territory
  • Patient does not have a known FRα expression from a previous test
  • Patient has not previously been tested under this program
  • Patient’s physician has determined that the test is clinically appropriate for the individual patient


Patients meeting the above eligibility criteria, as well as their treating health care providers, are not required to order, purchase, prescribe, and/or obtain any other product or service from ImmunoGen, Labcorp or any of their affiliates.

All eligible patients who enroll in the FR-ASSIST™ Sponsored Testing Program will receive one FOLR1 IHC test (test code 453027) at no charge.

Testing

How to participate

Choose between the following testing options:

NeoGenomics

FOLR1 IHC

Genes Evaluated: FOLR1

How To Order

To place your paper-based order, complete the NeoGenomics paper test request form for FOLR1, and fax it to 310-876-3216, or insert the form in the NeoGenomics specimen collection kit before shipment.

Order Here
Learn More

Labcorp

FOLR1 IHC

Genes Evaluated: FOLR1

How To Order

To place your paper-based order, complete the Labcorp intake form for FOLR1, and a program representative will be in touch with you to provide specifics about the program.

Order Here
Learn More

Myriad Genetics

FOLR1 IHC

Genes Evaluated: FOLR1

How To Order

To place your paper-based order, complete the Myriad Genetics paper test request form for FOLR1, and fax it to 310-876-3216, or insert the form in the Myriad Genetics specimen collection kit before shipment.

Order Here
Learn More

FAQs

Program Information

What role does folate receptor alpha (FRα) play in ovarian cancer?

Folate receptor alpha (FRα) is an actionable therapeutic target that is commonly expressed in ovarian cancer. Approximately 35% of ovarian cancer patients are expected to be positive for FRα expression by the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay.

Why should I test for folate receptor alpha (FRα) in my ovarian cancer cases?

With the approval of ELAHERE™ (mirvetuximab soravtansine-gynx), FRα is now an actionable target in platinum-resistant ovarian cancer.

Is this the companion diagnostic test for ELAHERE™ (mirvetuximab soravtansine-gynx)?

Yes; the labs listed above are validated to run the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the FDA-approved companion diagnostic for ELAHERE™.

Who should get tested for FOLR1 protein expression (also known as FRα)?

The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay is intended for use in the assessment of FRα in ovarian cancer, including epithelial ovarian cancer, primary peritoneal cancer or primary fallopian tube cancer. Because FRα is generally stable through the course of treatment, testing can be done upon diagnosis of ovarian cancer or at progression.

Can I use archival ovarian cancer tissue for testing?

Yes; Fresh or archival ovarian cancer tissue is acceptable for FOLR1 IHC CDx testing.

What are the specimen requirements for tissue?

The performing labs offer FOLR1 IHC CDx testing on formalin-fixed paraffin-embedded (FFPE) tumor resection or biopsy samples. Ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer and primary fallopian tube cancer) tissue is required. The paraffin block is preferred. Alternatively, send One (1) unbaked, unstained slide for H&E staining (required) and two to three (2-3) positively charged unstained slides (all cut at 4-5 microns). Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives or send decalcified specimens.

When can I expect the results?

Results are typically ready in 3-5 days from the time the specimen is received at the performing lab and will be sent to the ordering physician’s office or laboratory by their preferred method of delivery.

What if I get a bill?

No patient, health care program, or beneficiary shall be billed for this test as part of the testing program.

Can the performing lab retrieve the tissue FFPE block for testing?

Yes. Labcorp and NeoGenomics can procure the sample block from the designated pathology laboratory indicated in the completed test request form.

Myriad Genetics and PathAI Diagnostics require the block to be requested by the ordering physician. A shipping slip will be supplied.

 

More Information About This Program

  • Patients that meet the eligibility criteria may receive one test at no cost.
  • No patients, providers, and/or third-party payers (including commercial health plans and government health care programs) will be billed for the testing covered under the program.
  • The ordering physician will not receive any fees or other compensation in connection with the Sponsored Testing Program, such as for specimen collection, handling, or data reporting.
  • Patients meeting the above eligibility criteria, as well as their treating health care providers, are not required to order, purchase, prescribe, and/or obtain any other product or service from sponsor, the labs or any of their affiliates.
  • The performing labs reserve the right to rescind, revoke, or amend the program for any reason without notice.
  • Program is not valid where prohibited by law.
  • No identifiable patient data will be shared with sponsor as part of this program.

About AbbVie

At AbbVie, we are committed to transforming standards of care for multiple blood cancers while advancing a dynamic pipeline of investigational therapies across a range of cancer types. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world’s most widespread and debilitating cancers. As we work to have a remarkable impact on people’s lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

About ELAHERE®

ELAHERE® (mirvetuximab soravtansine-gynx) is a first-in-class antibody-drug conjugate (ADC) developed by ImmunoGen for the treatment of folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. ELAHERE combines a folate receptor alpha-binding antibody with a potent cytotoxic agent designed to selectively target and kill cancer cells. It is administered to patients who have received one to three prior systemic treatment regimens and is the first FDA-approved ADC for this indication. The approval is based on tumor response rate and duration of response, with continued approval contingent upon confirmatory trials. ELAHERE has demonstrated significant improvements in progression-free survival and overall response rates compared to standard chemotherapy, offering a promising new option for this challenging to treat cancer. However, it carries a boxed warning for severe ocular toxicity, including visual impairment and keratopathy, and requires regular ophthalmic examinations and prophylactic eye treatments during therapy.

Related Programs

Ovarian Cancer (OCRA)

Primary Condition:

Ovarian Cancer

Sponsor

Performing Lab

Color Logo
Casandra.AI | Sponsored Testing logo

No cost testing programs made available to providers for their patients.

X-twitter Linkedin
Customer Service
  • List Your Program
  • List Your Program
Quick Links
  • Audiology
  • Cardiology
  • Dermatology
  • Endocrinology
  • Hematology
  • Hepatology
  • Immunology
  • Metabolic
  • Nephrology
  • Neurology
  • Oncology
  • Ophthalmology
  • Skeletal
  • Urology
  • Women’s Health
  • Audiology
  • Cardiology
  • Dermatology
  • Endocrinology
  • Hematology
  • Hepatology
  • Immunology
  • Metabolic
  • Nephrology
  • Neurology
  • Oncology
  • Ophthalmology
  • Skeletal
  • Urology
  • Women’s Health
Get In Touch
  • Email: [email protected]
  • Phone: ‪(910) 319-1953‬
Receive Updates

Subscribe to receive notification of new sponsored testing programs.

© 2025 Casandra AI, Inc. All Rights Reserved.